Blood biomarkers will reshape who gets diagnosed, and when

Until recently, an in-vivo Alzheimer's biomarker meant either a CSF panel — requiring a lumbar puncture — or an amyloid or tau PET scan — requiring radiotracer infrastructure, scanner time, and Medicare coverage carve-outs. Both are clinically validated. Neither scales to a population in which an estimated six million Americans live with the disease and many millions more are in the prodromal phase.

Plasma assays have been changing that picture for several years. The shift from research interest to clinical adoption is now visible in three concurrent developments: laboratory-developed tests with credible analytical validation are commercially available; the LEADS-style multi-site comparisons have demonstrated real-world performance in heterogeneous populations; and several FDA-cleared in-vitro diagnostics have entered the market.

The diagnostic funnel is widening

In a PET-and-CSF world, the bottleneck on confirmed diagnosis was the biomarker test itself. In a plasma-biomarker world, the bottleneck moves earlier in the workflow — to the question of who gets tested at all. Primary care has historically referred slowly to specialty cognitive evaluation. A simple blood test with reasonable sensitivity and specificity in symptomatic populations changes the cost-benefit of that referral pattern.

The downstream consequences are predictable in direction, less so in magnitude:

• More confirmed diagnoses. Particularly among populations historically underserved by specialty referral pathways, including rural patients and underrepresented ethnic groups.
• Earlier diagnoses. Plasma biomarkers can be sensitive in MCI and even pre-symptomatic disease, raising disclosure and treatment-eligibility questions that the field has not fully resolved.
• Greater pressure on the post-diagnostic system. Specialist appointments, infusion capacity, MRI surveillance, and counselling resources all sit downstream of the diagnostic act.

What blood biomarkers do not solve

Plasma assays are decision-support tools, not standalone diagnostic instruments. The current best-in-class tests still have meaningful false-positive and false-negative rates, particularly outside the populations in which they were validated. Confirmatory imaging remains the standard before initiating disease-modifying therapy. The pre-analytical variability — sample handling, time-to-centrifugation, freeze-thaw — is more sensitive than for most routine clinical chemistry, and operational adoption requires careful workflow design.

There is also a population question. Most analytical validation has been done in cohorts that are not representative of the broader American patient population. Performance in real-world primary care, across a fully demographically diverse population, is still being characterized.

The implication

Blood biomarkers are not a marginal improvement in the diagnostic pathway. They are a structural change to who gets diagnosed and when. Health systems that anticipate the downstream load — counselling, treatment eligibility evaluation, longitudinal follow-up — will be better positioned than those that treat the test as a drop-in replacement for PET. The diagnostic act is becoming cheaper and easier. Everything that follows from a diagnosis is not.